Long-term follow-up of previously treated and treatment-naïve patients who received tositumomab and I-131 tositumomab

Leuk Lymphoma. 2016 May;57(5):1238-40. doi: 10.3109/10428194.2015.1082179. Epub 2015 Dec 23.

Authors

Thierry J Horner¹, Vanessa C Williams², Patricia Giampietro², Philip A Witman³, Thomas S Lin⁴

Affiliations

¹ a GlaxoSmithKline , Collegeville , PA , USA ;
² b Novartis Pharmaceuticals, Oncology Clinical Pharmacology , Morrisville , NC , USA ;
³ c Pfizer , Collegeville , PA , USA ;
⁴ d Janssen Pharmaceuticals , Horsham , PA , USA.

PMID: 26696131
DOI: 10.3109/10428194.2015.1082179

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antigens, CD20
Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Follow-Up Studies
Humans
Leukemia, Myeloid, Acute / metabolism
Leukemia, Myeloid, Acute / radiotherapy*
Myelodysplastic Syndromes / metabolism
Myelodysplastic Syndromes / radiotherapy*
Retreatment
Treatment Outcome

Substances

Antibodies, Monoclonal
Antigens, CD20
Antineoplastic Agents
tositumomab I-131